Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Adrenocorticotropin Hormone Secreting Carcinoma of the Pancreas: A Case Report.

Bleicher J, Lombardo S, Carbine S, Kapitonov D, Pletneva MA, Mulvihill SJ.

J Pancreat Cancer. 2019 Jun 20;5(1):22-25. doi: 10.1089/pancan.2019.0004. eCollection 2019.

2.

County-level Variation in Use of Surgery and Cancer-specific Survival for Stage I-II Pancreatic Adenocarcinoma.

Swords DS, Mulvihill SJ, Brooke BS, Stoddard GJ, Firpo MA, Scaife CL.

Ann Surg. 2019 Apr 8. doi: 10.1097/SLA.0000000000003236. [Epub ahead of print]

PMID:
30973391
3.

Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity.

Capello M, Vykoukal JV, Katayama H, Bantis LE, Wang H, Kundnani DL, Aguilar-Bonavides C, Aguilar M, Tripathi SC, Dhillon DS, Momin AA, Peters H, Katz MH, Alvarez H, Bernard V, Ferri-Borgogno S, Brand R, Adler DG, Firpo MA, Mulvihill SJ, Molldrem JJ, Feng Z, Taguchi A, Maitra A, Hanash SM.

Nat Commun. 2019 Jan 16;10(1):254. doi: 10.1038/s41467-018-08109-6.

4.

Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity.

Swords DS, Mulvihill SJ, Brooke BS, Skarda DE, Firpo MA, Scaife CL.

Surgery. 2019 Apr;165(4):751-759. doi: 10.1016/j.surg.2018.10.035. Epub 2018 Dec 11.

PMID:
30551868
5.

Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy.

Swords DS, Francis SR, Lloyd S, Garrido-Laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL.

J Gastrointest Surg. 2019 Jul;23(7):1401-1413. doi: 10.1007/s11605-018-3953-0. Epub 2018 Sep 5.

PMID:
30187332
6.

Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: Do the 2017 International Consensus Guidelines improve clinical decision making?

Sharib JM, Fonseca AL, Swords DS, Jaradeh K, Bracci PM, Firpo MA, Hatcher S, Scaife CL, Wang H, Kim GE, Mulvihill SJ, Maitra A, Koay EJ, Kirkwood KS.

Surgery. 2018 Dec;164(6):1178-1184. doi: 10.1016/j.surg.2018.07.014. Epub 2018 Aug 28.

PMID:
30170819
7.

Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma.

Swords DS, Mulvihill SJ, Firpo MA, Scaife CL.

JAMA Oncol. 2018 Aug 1;4(8):1129-1130. doi: 10.1001/jamaoncol.2018.2442. No abstract available.

8.

Pancreatic cancer as a sentinel for hereditary cancer predisposition.

Young EL, Thompson BA, Neklason DW, Firpo MA, Werner T, Bell R, Berger J, Fraser A, Gammon A, Koptiuch C, Kohlmann WK, Neumayer L, Goldgar DE, Mulvihill SJ, Cannon-Albright LA, Tavtigian SV.

BMC Cancer. 2018 Jun 27;18(1):697. doi: 10.1186/s12885-018-4573-5.

9.

Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery.

Swords DS, Zhang C, Presson AP, Firpo MA, Mulvihill SJ, Scaife CL.

Surgery. 2018 Apr;163(4):753-760. doi: 10.1016/j.surg.2017.10.054. Epub 2017 Dec 13.

PMID:
29248179
10.

Hospital-level Variation in Utilization of Surgery for Clinical Stage I-II Pancreatic Adenocarcinoma.

Swords DS, Mulvihill SJ, Skarda DE, Finlayson SRG, Stoddard GJ, Ott MJ, Firpo MA, Scaife CL.

Ann Surg. 2019 Jan;269(1):133-142. doi: 10.1097/SLA.0000000000002404.

PMID:
28700442
11.

Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.

Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw266.

12.

Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma.

Swords DS, Firpo MA, Johnson KM, Boucher KM, Scaife CL, Mulvihill SJ.

Surgery. 2017 Jul;162(1):104-111. doi: 10.1016/j.surg.2016.12.029. Epub 2017 Feb 21.

13.

Biomarkers in pancreatic adenocarcinoma: current perspectives.

Swords DS, Firpo MA, Scaife CL, Mulvihill SJ.

Onco Targets Ther. 2016 Dec 9;9:7459-7467. doi: 10.2147/OTT.S100510. eCollection 2016. Review.

14.

Initial Misdiagnosis of Proximal Pancreatic Adenocarcinoma Is Associated with Delay in Diagnosis and Advanced Stage at Presentation.

Swords DS, Mone MC, Zhang C, Presson AP, Mulvihill SJ, Scaife CL.

J Gastrointest Surg. 2015 Oct;19(10):1813-21. doi: 10.1007/s11605-015-2923-z. Epub 2015 Aug 19.

PMID:
26286368
15.

Early detection of sporadic pancreatic cancer: summative review.

Chari ST, Kelly K, Hollingsworth MA, Thayer SP, Ahlquist DA, Andersen DK, Batra SK, Brentnall TA, Canto M, Cleeter DF, Firpo MA, Gambhir SS, Go VL, Hines OJ, Kenner BJ, Klimstra DS, Lerch MM, Levy MJ, Maitra A, Mulvihill SJ, Petersen GM, Rhim AD, Simeone DM, Srivastava S, Tanaka M, Vinik AI, Wong D.

Pancreas. 2015 Jul;44(5):693-712. doi: 10.1097/MPA.0000000000000368. Review.

16.

Defective apical extrusion signaling contributes to aggressive tumor hallmarks.

Gu Y, Shea J, Slattum G, Firpo MA, Alexander M, Mulvihill SJ, Golubovskaya VM, Rosenblatt J.

Elife. 2015 Jan 26;4:e04069. doi: 10.7554/eLife.04069.

17.

Value Driven Outcomes (VDO): a pragmatic, modular, and extensible software framework for understanding and improving health care costs and outcomes.

Kawamoto K, Martin CJ, Williams K, Tu MC, Park CG, Hunter C, Staes CJ, Bray BE, Deshmukh VG, Holbrook RA, Morris SJ, Fedderson MB, Sletta A, Turnbull J, Mulvihill SJ, Crabtree GL, Entwistle DE, McKenna QL, Strong MB, Pendleton RC, Lee VS.

J Am Med Inform Assoc. 2015 Jan;22(1):223-35. doi: 10.1136/amiajnl-2013-002511. Epub 2014 Oct 16.

18.

Factors associated with improved survival after resection of pancreatic adenocarcinoma: a multivariable model.

Call TR, Pace NL, Thorup DB, Maxfield D, Chortkoff B, Christensen J, Mulvihill SJ.

Anesthesiology. 2015 Feb;122(2):317-24. doi: 10.1097/ALN.0000000000000489.

PMID:
25305092
19.

Screening for pancreatic cancer.

Poruk KE, Firpo MA, Mulvihill SJ.

Adv Surg. 2014;48:115-36. Review.

PMID:
25293611
20.

HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer.

Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM.

NMR Biomed. 2014 Nov;27(11):1361-70. doi: 10.1002/nbm.3198. Epub 2014 Sep 9.

21.

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93.

PMID:
25099441
22.

Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers.

Firpo MA, Boucher KM, Mulvihill SJ.

Theor Biol Med Model. 2014 Aug 5;11:34. doi: 10.1186/1742-4682-11-34.

23.

The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma.

von Figura G, Fukuda A, Roy N, Liku ME, Morris Iv JP, Kim GE, Russ HA, Firpo MA, Mulvihill SJ, Dawson DW, Ferrer J, Mueller WF, Busch A, Hertel KJ, Hebrok M.

Nat Cell Biol. 2014 Mar;16(3):255-67. doi: 10.1038/ncb2916. Epub 2014 Feb 23.

24.

Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.

Kendrick ZW, Firpo MA, Repko RC, Scaife CL, Adler DG, Boucher KM, Mulvihill SJ.

HPB (Oxford). 2014 Jul;16(7):670-6. doi: 10.1111/hpb.12199. Epub 2013 Dec 6.

25.

Does travel distance influence length of stay in elective pancreatic surgery?

Jackson KL, Glasgow RE, Mone MC, Sheng X, Mulvihill SJ, Scaife CL.

HPB (Oxford). 2014 Jun;16(6):543-9. doi: 10.1111/hpb.12180. Epub 2013 Nov 7.

26.

Association between postoperative complications and clinical cancer outcomes.

Scaife CL, Hartz A, Pappas L, Pelletier P, He T, Glasgow RE, Mulvihill SJ.

Ann Surg Oncol. 2013 Dec;20(13):4063-6. doi: 10.1245/s10434-013-3267-0. Epub 2013 Sep 20.

PMID:
24052315
27.

Comparison of intraoperative versus delayed enteral feeding tube placement in patients undergoing a Whipple procedure.

Scaife CL, Hewitt KC, Mone MC, Hansen HJ, Nelson ET, Mulvihill SJ.

HPB (Oxford). 2014 Jan;16(1):62-9. doi: 10.1111/hpb.12072. Epub 2013 Mar 8.

28.

Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.

Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ.

Pancreas. 2013 Mar;42(2):193-7. doi: 10.1097/MPA.0b013e31825e354d.

29.

The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ.

Curr Mol Med. 2013 Mar;13(3):340-51. Review.

30.

Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel.

Granger JH, Granger MC, Firpo MA, Mulvihill SJ, Porter MD.

Analyst. 2013 Jan 21;138(2):410-6. doi: 10.1039/c2an36128k.

31.

Screening for pancreatic cancer: why, how, and who?

Poruk KE, Firpo MA, Adler DG, Mulvihill SJ.

Ann Surg. 2013 Jan;257(1):17-26. doi: 10.1097/SLA.0b013e31825ffbfb. Review.

32.

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA; National Comprehensive Cancer Networks.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):703-13.

33.

Roux-en-Y drainage of a pancreatic fistula for disconnected pancreatic duct syndrome after acute necrotizing pancreatitis.

Pearson EG, Scaife CL, Mulvihill SJ, Glasgow RE.

HPB (Oxford). 2012 Jan;14(1):26-31. doi: 10.1111/j.1477-2574.2011.00397.x. Epub 2011 Oct 31.

34.

Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression.

Fukuda A, Wang SC, Morris JP 4th, Folias AE, Liou A, Kim GE, Akira S, Boucher KM, Firpo MA, Mulvihill SJ, Hebrok M.

Cancer Cell. 2011 Apr 12;19(4):441-55. doi: 10.1016/j.ccr.2011.03.002.

35.

Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.

Poruk KE, Firpo MA, Huerter LM, Scaife CL, Emerson LL, Boucher KM, Jones KA, Mulvihill SJ.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2605-10. doi: 10.1158/1055-9965.EPI-10-0178. Epub 2010 Aug 20.

36.

Prognostic significance of PINCH signalling in human pancreatic ductal adenocarcinoma.

Scaife CL, Shea J, Emerson L, Boucher K, Firpo MA, Beckerle MC, Mulvihill SJ.

HPB (Oxford). 2010 Jun;12(5):352-8. doi: 10.1111/j.1477-2574.2010.00177.x.

37.

A population-based description of familial clustering of pancreatic cancer.

Shirts BH, Burt RW, Mulvihill SJ, Cannon-Albright LA.

Clin Gastroenterol Hepatol. 2010 Sep;8(9):812-6. doi: 10.1016/j.cgh.2010.05.012. Epub 2010 May 23.

PMID:
20570637
38.

Phenotype and genotype of pancreatic cancer cell lines.

Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ.

Pancreas. 2010 May;39(4):425-35. doi: 10.1097/MPA.0b013e3181c15963. Review. Erratum in: Pancreas. 2018 Jul;47(6):e37.

39.

ACS-NSQIP has the potential to create an HPB-NSQIP option.

Pitt HA, Kilbane M, Strasberg SM, Pawlik TM, Dixon E, Zyromski NJ, Aloia TA, Henderson JM, Mulvihill SJ.

HPB (Oxford). 2009 Aug;11(5):405-13. doi: 10.1111/j.1477-2574.2009.00074.x.

40.

NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX.

J Natl Compr Canc Netw. 2009 Apr;7(4):350-91. No abstract available.

41.

Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.

Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ.

World J Surg. 2009 Apr;33(4):716-22. doi: 10.1007/s00268-008-9853-9.

42.

Gastrointestinal perforation and the acute abdomen.

Langell JT, Mulvihill SJ.

Med Clin North Am. 2008 May;92(3):599-625, viii-ix. doi: 10.1016/j.mcna.2007.12.004. Review.

PMID:
18387378
43.

Natural history of pancreatic cancer recurrence following "curative" resection in athymic mice.

Torgenson MJ, Shea JE, Firpo MA, Dai Q, Mulvihill SJ, Scaife CL.

J Surg Res. 2008 Sep;149(1):57-61. doi: 10.1016/j.jss.2007.08.024. Epub 2007 Sep 18.

PMID:
18222475
44.

Synthetic extracellular matrix enhances tumor growth and metastasis in an orthotopic mouse model of pancreatic adenocarcinoma.

Scaife CL, Shea JE, Dai Q, Firpo MA, Prestwich GD, Mulvihill SJ.

J Gastrointest Surg. 2008 Jun;12(6):1074-80. Epub 2007 Dec 5.

PMID:
18057994
45.

Subcutaneous tumor seeding following needle core biopsy of hepatocellular carcinoma.

Rowe LR, Mulvihill SJ, Emerson L, Gopez EV.

Diagn Cytopathol. 2007 Nov;35(11):717-21.

PMID:
17924404
46.

Pancreatic resection in Veterans Affairs and selected university medical centers: results of the patient safety in surgery study.

Glasgow RE, Jackson HH, Neumayer L, Schifftner TL, Khuri SF, Henderson WG, Mulvihill SJ.

J Am Coll Surg. 2007 Jun;204(6):1252-60.

PMID:
17544083
47.

Anti-inflammatory effects of PPAR-gamma agonists directly correlate with PPAR-gamma expression during acute pancreatitis.

Rollins MD, Sudarshan S, Firpo MA, Etherington BH, Hart BJ, Jackson HH, Jackson JD, Emerson LL, Yang DT, Mulvihill SJ, Glasgow RE.

J Gastrointest Surg. 2006 Sep-Oct;10(8):1120-30.

PMID:
16966031
48.

Hepatobiliary cancers. Clinical practice guidelines in oncology.

Benson AB 3rd, Bekaii-Saab T, Ben-Josef E, Blumgart L, Clary BM, Curley SA, Davila R, Earle CC, Ensminger WD, Gibbs JF, Laheru D, Langnas AN, Mulvihill SJ, Nemcek AA Jr, Posey JA, Sigurdson ER, Sinanan M, Vauthey JN, Venook AP, Wagman LD, Yeatman TJ; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Sep;4(8):728-50. No abstract available.

PMID:
16948952
49.

Lessons learned from laparoscopic treatment of gastric and gastroesophageal junction stromal cell tumors.

Granger SR, Rollins MD, Mulvihill SJ, Glasgow RE.

Surg Endosc. 2006 Aug;20(8):1299-304. Epub 2006 Jul 24.

PMID:
16865626
50.

Development of a dedicated hepatopancreaticobiliary program in a university hospital system.

Granger SR, Glasgow RE, Battaglia J, Lee RM, Scaife C, Shrieve DC, Avrin D, Mulvihill SJ.

J Gastrointest Surg. 2005 Sep-Oct;9(7):891-5.

PMID:
16137580

Supplemental Content

Loading ...
Support Center